Table 1 Baseline demographic and clinical characteristics of the study population stratified by GLR tertile.
Total (n = 314) | Tertile 1 (n = 106) | Tertile 2 (n = 104) | Tertile 3 (n = 104) | P value | |
|---|---|---|---|---|---|
Demographics | |||||
Age (year) | 52 (42, 61) | 51 (37, 59) | 50 (41, 60) | 56 (45, 63) | 0.027 |
Male n (%) | 145 (46.18) | 44 (41.51) | 53 (50.96) | 48 (46.15) | 0.389 |
Body mass index (kg/m2) | 21.72 (19.72, 23.95) | 21.69 (19.22, 24.17) | 22.58 (20.08, 24.04) | 21.31 (19.13, 23.65) | 0.101 |
Causes of end-stage kidney disease | 0.852 | ||||
Chronic glomerulonephritis n (%) | 190 (60.51) | 62 (58.49) | 66 (63.46) | 62 (59.62) | |
Diabetic nephropathy n (%) | 51 (16.24) | 20 (18.87) | 12 (11.54) | 19 (18.27) | |
Hypertensive nephropathy n (%) | 41 (13.06) | 13 (12.26) | 15 (14.42) | 13 (12.50) | |
Others n (%) | 32 (10.19) | 11 (10.38) | 11 (10.58) | 10 (9.62) | |
Comorbidities | |||||
Cardiovascular disease n (%) | 46 (14.65) | 18 (16.98) | 13 (12.50) | 15 (14.42) | 0.654 |
Diabetes n (%) | 59 (18.79) | 22 (20.75) | 15 (14.42) | 22 (21.15) | 0.377 |
Use of antidiabetic drugs n (%) | 51 (16.24) | 18 (16.98) | 13 (12.50) | 20 (19.23) | 0.407 |
Laboratory variables | |||||
Hemoglobin (g/L) | 76 (63, 90) | 79 (66, 96) | 78 (65, 91) | 68 (56, 84) | < 0.001 |
White blood count (109/L) | 5.45 (4.47, 7.01) | 5.68 (4.83, 7.19) | 5.28 (4.37, 7.02) | 5.47 (4.13, 6.91) | 0.103 |
Leukocyte count (109/L) | 0.98 (0.75, 1.22) | 1.34 (1.18, 1.63) | 0.95 (0.85, 1.07) | 0.65 (0.52, 0.77) | < 0.001 |
Platelet count (109/L) | 142 (103, 180) | 156 (123, 194) | 132 (99, 162) | 129 (92, 170) | 0.001 |
High-sensitivity C-reactive protein (mg/L) | 1.60 (0.79, 5.20) | 1.50 (0.50, 4.09) | 1.40 (0.80, 3.70) | 2.90 (1.00, 12.65) | 0.091 |
Serum creatinine (µmol/L) | 804.0 (666.3, 1018.3) | 760.5 (637.3, 901.3) | 851.5 (714.5, 1088.3) | 839.0 (656.3, 1076.8) | 0.009 |
Serum urea nitrogen (mmol/L) | 29.93 (23.14, 39.55) | 26.02 (19.49, 34.66) | 31.62 (24.02, 38.30) | 36.15 (24.44, 43.84) | < 0.001 |
Serum uric acid (µmol/L) | 495.0 (408.8, 596.5) | 465.5 (403.5, 569.5) | 510.0 (421.3, 632.3) | 501.5 (415.8, 591.0) | 0.196 |
Serum corrected calcium (mmol/L) | 2.09 (1.84, 2.24) | 2.17 (1.95, 2.29) | 2.02 (1.82, 2.19) | 2.04 (1.73, 2.22) | < 0.001 |
Serum phosphorus (mmol/L) | 1.92 (1.56, 2.30) | 1.85 (1.51, 2.19) | 1.90 (1.62, 2.30) | 2.00 (1.57, 2.44) | 0.249 |
Serum albumin (g/L) | 33.44 ± 5.62 | 32.75 ± 6.57 | 34.56 ± 4.60 | 33.01 ± 5.38 | 0.041 |
Fasting blood glucose (mmol/L) | 4.80 (4.37, 5.40) | 4.50 (4.11, 4.80) | 4.85 (4.46, 5.31) | 5.20 (4.73, 6.12) | < 0.001 |
GLR | 5.08 (3.79, 6.83) | 3.27 (2.90, 3.80) | 5.11 (4.60, 5.40) | 8.23 (6.84, 10.19) | < 0.001 |
Intact parathyroid hormone (pg/mL) | 335 (179, 479) | 267 (142, 444) | 368 (217, 529) | 351 (203, 495) | 0.018 |
Dialysis-related data | |||||
Daily ultrafiltration (mL) | 337.52 ± 447.43 | 293.33 ± 429.67 | 364.60 ± 510.67 | 355.75 ± 397.95 | 0.520 |
24-hour urine volume (mL) | 900 (500, 1300) | 825 (500, 1300) | 1100 (600, 1500) | 800 (500, 1200) | 0.045 |
Total weekly Kt/V | 2.11 (1.76, 2.51) | 2.13 (1.80, 2.61) | 2.00 (1.73, 2.41) | 2.18 (1.82, 2.52) | 0.543 |
Glucose exposure (g) | 115 (90, 120) | 90 (90, 120) | 90 (90, 120) | 120 (90, 120) | 0.125 |
Peritonitis | |||||
Peritonitis episode n (%) | 123 (39.17) | 34 (32.08) | 39 (37.50) | 50 (48.08) | 0.054 |
Follow-up time (months) | 27 (13, 50) | 35 (15, 55) | 27 (15, 52) | 24 (10, 41) | 0.076 |
